Abbott’s Earnings Guidance Unchanged With Questions On Formula Recall Unanswered

Latest announcement about recall not reported in SEC filing came in FDA posting of Abbott’s announcement concerning an expansion of firm’s recall to include an additional lot of Similac powder.

• Source: Alamy

Abbott Laboratories Ltd maintains its full-year earnings guidance despite one-time costs of an undetermined amount it will incur related to its ongoing recall of Similac and other infant formula brands made at a plant where bacterial contaminations were found.

The US Food and Drug Administration says, upon completing its investigation of facility operated by the firm's Abbott Nutrition division...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Recalls

More from Policy & Regulation